Takayasu arteritis-associated pulmonary hypertension.

Area of Science:

• Cardiology
• Rheumatology
• Pulmonology

Background:

• Takayasu arteritis (TA) is a rare, chronic inflammatory disease affecting large arteries, primarily the aorta and its branches.
• Pulmonary hypertension (PH) is a serious complication that can arise in patients with TA, significantly impacting prognosis.
• Understanding the pathogenesis, clinical presentation, and treatment of PH in TA is crucial for improving patient outcomes.

Purpose of the Study:

• To investigate the pathogenesis, clinical features, diagnosis, and therapy of pulmonary hypertension (PH) in patients with Takayasu arteritis (TA).
• To compare the characteristics and treatment responses of PH in TA with pulmonary artery involvement (PA) versus idiopathic pulmonary arterial hypertension (IPAH).
• To evaluate the effectiveness of PH-specific therapies and pulmonary artery revascularization in TA patients.

Main Methods:

• A cohort study involving 48 TA patients with PH, 20 TA patients with PA without PH, and 30 IPAH patients.
• Data collected included clinical features, diagnosis, serum big endothelin 1 (ET-1) levels, and right heart catheterization findings.
• Follow-up assessments included treatment responses to vasodilators, outcomes after pulmonary artery revascularization, and mortality.

Main Results:

• Of 48 TA patients with PH, 75% had pulmonary artery involvement (PA) and 25% had left heart disease (LHD).
• Serum ET-1 levels correlated with pulmonary arterial systolic pressure in TA patients with PH.
• TA patients with PH due to PA showed lower cardiac indexes but a 100% favorable response to vasodilator testing, unlike IPAH patients (33.3%). Revascularization yielded good prognoses in selected cases.

Conclusions:

• Patients with Takayasu arteritis are at an elevated risk for developing pulmonary hypertension.
• Early screening for PH in TA patients presenting with unexplained symptoms is recommended.
• PH-specific therapies and revascularization may be effective treatments for early-stage PA, PH, and severe pulmonary artery stenosis in TA.